AIIMS Jodhpur · AIIMS/JDH/SPH/2026/268

A Phase III, Multicentre, Randomized, double-Blind, Placebo Controlled study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophillized) – "DengiAll" of Panacea Biotec Limited in Healthy Indian Adults" under NHRP (Vector borne component) 2026

Applications closed closed 17 Jul 2026

Checked 56 minutes ago

All India Institute of Medical Sciences, Jodhpur is recruiting A Phase III, Multicentre, Randomized, double-Blind, Placebo Controlled study to Evaluate the Efficacy, Immunogenicity and Safety of Single dose of Dengue Tetravalent Vaccine, Live Attenuated (Recombinant, Lyophillized) – "DengiAll" of Panacea Biotec Limited in Healthy Indian Adults" under NHRP (Vector borne component). Applications opened 06 July and close 17 July 2026. Advertisement AIIMS/JDH/SPH/2026/268.

This drive does not publish a state-by-state vacancy table, or we have not been able to read one from it yet — so this page does not show one.

Apply on All India Institute of Medical Sciences, Jodhpur aiimsjodhpur.edu.in We never fill forms and never ask for a portal login — applications happen on AIIMSJ's own site. The calendar entry lives on your device: no account, and nothing we can send you later.

Applications open	06 Jul 2026
Last date	17 Jul 2026
Age	not read yet
Qualification	not read yet
Fee	not read yet
Advertisement	AIIMS/JDH/SPH/2026/268

Blanks are ours, not the document's. Every filled value was read from the notification linked below; anything marked not read yet is a gap in our reading, not a field the recruiter left empty.

Sourced. Read from 1783318334_Advertisement for DengiAll Project-060726.pdf — the official AIIMSJ notification (aiimsj-table).
Not checked. No state-by-state table could be read from this document, so there was no arithmetic to reconcile. The dates and identifiers above come from the document itself.
Fetched 31 Aug 2026, 03:48 UTC.